Published 2019-01-09
Widya Sakti Pratama Soetojo Soetojo Lukman Hakim


Objective: To determine the combination effect of celecoxib and gemcitabine-carboplatin chemotherapy to the apoptosis of cultured-urothelial cancer cell line. Material & Methods: Urothelial carcinoma cell line originating from Bladder Ca 5637 was cultured and used in this in vitro study. Three-groups of cultured-urothelial cancer cell line consisted of (1) control (C), (2) gemcitabine-carboplatin treated group (GC) and (3) gemcitabine-carboplatin and celecoxib treated group (GCC) were treated with 0.086 µM gemcitabine, 290 µM carboplatin and 25 µM celecoxib. All groups were evaluated at 24 hours following treatment, and the apoptotic index (AI) measured accordingly. Results: Significant mean apoptotic index differences were found between the C and GC group; and between C and GCC groups at 24 hours following treatment. However, the AI of GCC was lower than the GC group although not statistically significant (p>0.05). Conclusion: Our study have shown that gemcitabine-carboplatin and the combination of both with celecoxib may increase the apoptosis of urothelial cancer cell line. The role of celecoxib in the addition of gemcitabine-carboplatin to treat urothelial cancer cell line needs to be elucidated further. 



Gemcitabine, carboplatin, celecoxib, bladder carcinoma, apoptosis


Kirkali Z, Chan T, Manoharan M, Algaba F, Busch C, Cheng L, et al. Bladder cancer: Epidemiology, staging and grading, and diagnosis. Urology. 2005; 66 (6 Suppl. 1): 4–34.

Messing EM, Wein AJ. Urothelial tumor of the bladder. In: Campbell Walsh Urology. 9th ed. Philadelphia: Saunders Elsevier; 2007.

Stenzl A, Cowan NC, De Santis M. Guidelines on muscle invasive and metastatic bladder cancer. In: Parson KF, Irani J, Chapple CR, editor. EAU Guidelines. European Association of Urology; 2010. p. 5–52.

Eble JN, Sauter G. Tumours of the urinary system. In: Pathology and Genetics of Tumours of The Urinary System and Male Genital Organ. Lyon: IARC Press; 2002. p. 89–147.

Irani J, Heidenreich A, Mottet N, Lechevallier E. What is new in bladder cancer diagnosis and management? Eur Urol Suppl. 2008; 7(6): 484–93.

Bernie JE, Schmidt JD. Bladder cancer. In: Vademecum ND, editor. Urological Oncology. Texas: Landes Bioscience; 2005. p. 53–63.

Babjuk M. Guidelines on non-muscle invasive bladder cancer. In: Parsons KF, Irani J, Chapple CR, editor. EAU Guidelines. European Association of Urology; 2010. p. 3–17.

Subbaramaiah K, Altorkil N, Chung WJ, Mestre JR, Sampat A, Dannenberg AJ. Inhibition of cyclooxygenase-2 gene expression by p53. J Biol Chem. 1999; 274(16): 10911–5.

Half E, Ming Tang X, Gwyn K, Sahin A, Wathen K, Sinicrope FA. Cyclooxygenase-2 Expression in human breast cancers and adjacent ductal carcinoma in situ1. Cancer Res. 2002; 62(38): 1676–81.

Schmedtje JF, Ji YS, Liu WL, DuBois RN, Runge MS. Hypoxia induces cyclooxygenase-2 via the NF-B p65 transcription factor in human vascular endothelial cells. J Biol Chem. 1997; 272(1): 601–8.

Mcllwain. Caspace functions in cell death and disease. In: Perspective in Biology. 5th ed. Cold Spring Harbor; 2013.

Yamamoto Y, Yin M-J, Lin K-M, Gaynor RB. Sulindac inhibits activation of the NF-[kappa]B pathway. J Biol Chem. 1999; 274(38): 27307–14.

Fischer J, Robin GC. Analogue-based Drug Discovery. John Wiley and Sons; 2006. 513 hal.

Ho YP, Au-Yeung SCF, To KKW. Platinum-based anticancer agents: Innovative design strategies and biological perspectives. Medicinal Research Reviews. 2003; 23: 633–55.

The American Society of Health-System Pharmacists. Carboplatin; 2016.

Subbaramaiah K, Dannenberg AJ. Cyclooxygenase 2: a molecular target for cancer prevention and treatment. Trends Pharmacol Sci. 2003; 24(2): 96–102.

Rouzer CA, Marnett LJ. Cyclooxygenases: structural and functional insights. J Lipid Res. 2009; 50(Suppl): S29–34.

Mohammed SI, Bennett PF, Craig BA, Glickman NW, Mutsaers AJ, Snyder PW, et al. Effects of the cyclooxygenase inhibitor, piroxicam, on tumor response, apoptosis, and angiogenesis in a canine model of human invasive urinary bladder cancer. Cancer Res. 2002; 62(2): 356–8.

Tiano HF, Loftin CD, Akunda J, Lee CA, Spalding J, Sessoms A, et al. Deficiency of either cyclooxygenase (COX)-1 or COX-2 alters epidermal differentiation and reduces mouse skin tumorigenesis. Cancer Res. 2002; 62(12): 3395–401.

Grösch S, Tegeder I, Niederberger E, Bräutigam L, Geisslinger G. COX-2 independent induction of cell cycle arrest and apoptosis in colon cancer cells by the selective COX-2 inhibitor celecoxib. FASEB J. 2001; 15(14): 2742–4.

Buttar NS, Wang KK, Leontovich O, Westcott JY, Pacifico RJ, Anderson MA, et al. Chemoprevention of esophageal adenocarcinoma by COX-2 inhibitors in an animal model of Barrett’s esophagus. Gastroenterology. 2002; 122(4): 1101–12.

Grubbs CJ, Lubet RA, Koki AT, Leahy KM, Masferrer JL, Steele VE, et al. Celecoxib inhibits bladder cancers in male B6D2F1 mice and female fischer-344 rats bladder cancers in male B6D2F1 mice and female fischer-344 rats. Animals. 2000; (21): 5599–602.

Giovannetti E, Danesi R, Mey V, Nannizzi S, Pasqualetti G, Del Tacca M. In vitro studies on gemcitabine combinations with other antiblastics. Ann Oncol. 2006; 17(Suppl. 5): 17–9.

Moore AS, Kitchell BE. New chemotherapy agents in veterinary medicine. Veterinary Clinics of North America - Small Animal Practice. 2003; 33: 629–49.

Solomon DH, Avorn J, Stürmer T, Glynn RJ, Mogun H, Schneeweiss S. Cardiovascular outcomes in new users of coxibs and nonsteroidal antiinflammatory drugs: High-risk subgroups and time course of risk. Arthritis Rheum. 2006; 54(5): 1378–89.

Yu L, Chen M, Li Z, Wen J, Fu J, Guo D, et al. Celecoxib antagonizes the cytotoxicity of cisplatin in human esophageal squamous cell carcinoma cells by reducing intracellular cisplatin accumulation. Mol Pharmacol. 2011; 79(3): 608–17.

Shi L, Zhong D, Gu C, Yu L. Celecoxib antagonizes the cytotoxic effect of carboplatin in human esophageal cancer cells. J South Med Univ. 2014; 34(6): 792–7.

Hall MD, Okabe M, Shen D-W, Liang X-J, Gottesman MM. The role of cellular accumulation in determining sensitivity to platinum-based chemotherapy. Annu Rev Pharmacol Toxicol. 2008; 48(1): 495–535.

Howell SB, Safaei R, Larson CA, Sailor MJ. Copper transporters and the cellular pharmacology of the platinum-containing cancer drugs. Mol Pharmacol. 2010; 77(6): 887–94.

Kelland L. The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer. 2007; 7(8): 573–84.

Copyright Information
Department of Urology, Faculty of Medicine/Airlangga University